about
Addition of a second opioid may improve opioid response in cancer pain: preliminary data.Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients.Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS)Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.Management of painful bone metastases.Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.Opioid switching in cancer pain: From the beginning to nowadays.Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care.Opioid switching and burst ketamine to improve the opioid response in patients with movement-related pain due to bone metastases.Switching from oxycodone to methadone in advanced cancer patients.The use of bisphosphonates in the management of bone metastatic prostate cancer.Opioids and renal function.How to use octreotide for malignant bowel obstruction.Localization of the sentinel lymph node in breast cancer: prospective comparison of vital staining and radioactive tracing methods.Opioid switching: a systematic and critical review.Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review.Opioid titration in cancer pain: a critical review.Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction.Pharmacological management of cancer pain in the elderly.The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus.The role of OROS hydromorphone in the management of cancer pain.Pain in patients with lung cancer: pathophysiology and treatment.Sexual issues in early and late stage cancer: a review.Intravenous patient-controlled analgesia and management of pain in post-surgical elderly with cancer.Intravenous morphine for management of cancer pain.Current knowledge of buprenorphine and its unique pharmacological profile.The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.Managing breakthrough pain.Spinal analgesia for advanced cancer patients: an update.Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review.Pharmacotherapy for breakthrough cancer pain.Octreotide for malignant bowel obstruction: twenty years after.The effect of age on opioid switching to methadone: a systematic review.Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit.Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.The anesthesiologist and end-of-life care.Opioid switching in patients with advanced cancer followed at home. A retrospective analysis.US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioids: pros and cons, and a European perspective.Combined oral prolonged-release oxycodone and naloxone in chronic pain management.The long and winding road of non steroidal antinflammatory drugs and paracetamol in cancer pain management: a critical review.
P50
Q30939189-40B65976-24D1-4CAD-A4F9-4FD57F01AB3EQ31077056-75DF6B9E-AD87-4158-83B5-473CEEC49694Q31143906-698D042D-746A-489C-B0ED-F68793CC89D4Q33866721-DAF4C009-E3A5-4745-8B04-A778010A3B93Q34004523-A6C94CB2-D52B-47E1-8261-7A3AB675DF06Q34251507-42DD8D74-7E7D-4FB6-99AD-724AEFAF6724Q34510628-F3D58AD7-3C3A-4BF2-8D36-C78563F09B88Q34539972-D5F5C09E-71B3-4358-9D26-2ABCE6AB76A6Q34610967-34025C94-7E47-4DB8-8338-9221EB8F8407Q34632120-823D4335-0BA3-424A-A970-E703C052F048Q34707134-58FB2005-E7C2-46D0-B2A8-FC412BAC29A2Q35671820-A1364C97-331A-48C0-B3F8-AB4B4EB40BEDQ35882704-ABF13592-4DD5-421D-97C4-D2E3E05223E7Q35955934-CB3A365B-A267-468F-98F6-BC8705384423Q36453600-EF6B5323-E2F6-4086-B9DB-8D57174DFAF9Q36729168-F368F592-AB9B-4340-837A-4FFE3D833FDDQ36748760-32A48B33-B230-4970-8F35-8E0A46D559AEQ36838057-87F20BDE-E57A-4394-B410-4D5F2E23F9C3Q36922229-8B8BA8BA-7EA5-403F-AFFE-03AA6CDC2473Q37478601-9782796E-4BE2-4603-AB19-B9BA78ED9BBFQ37623065-868CDFED-D3A6-4041-8572-EBDCD5ACA6A8Q37652913-D22AE966-A363-412A-AEAD-9DD87F7C2A9EQ37711065-B338B7B7-3C56-4EA3-99B8-4D109D10000BQ37728568-6F43EB4B-B34B-441C-9CB8-3836EF63C49DQ37740515-D7849FDC-5F70-46CB-A4FB-9F80A038AFAFQ37759279-BB7DB9C0-DD51-483F-923B-448208118D21Q37826856-962325F8-78AC-4331-A16A-A5382DAC0D67Q37855651-0B78551C-B08A-4CEC-9B63-0FA79DA50073Q37891441-91C8D4D4-38BE-4F28-AD71-B9F62A25F36DQ37894998-F70F1233-4B6C-4C42-BBDB-69249A846E3EQ37974707-36A0F050-4DFE-4BC5-8ACE-8FC7CE40A8AAQ37978727-9EAFB3B1-4E44-4979-8A90-E1BD1A5EC034Q37986765-C3F8B8B8-73C2-47D0-9ED9-D1E8F6914202Q37987626-871B011D-8B0F-436A-8B12-A7B010A806DAQ37994343-9686BB82-2EC2-46CE-9573-90049438BC2CQ37998294-48B78FEA-5CE3-4C18-A13D-3DC3D9EA6ECBQ38055912-2AF3916E-7DEC-4996-8DAD-F78700118133Q38056973-355D65B6-658F-44B3-9029-209CEC81EDC9Q38065187-89CD9AD3-E354-4250-9BB7-0D5026192863Q38080300-1493F269-00F5-4E16-B183-F407E7F52C1A
P50
description
researcher ORCID ID = 0000-0001-9859-6487
@en
wetenschapper
@nl
name
Sebastiano Mercadante
@ast
Sebastiano Mercadante
@en
Sebastiano Mercadante
@es
Sebastiano Mercadante
@nl
type
label
Sebastiano Mercadante
@ast
Sebastiano Mercadante
@en
Sebastiano Mercadante
@es
Sebastiano Mercadante
@nl
prefLabel
Sebastiano Mercadante
@ast
Sebastiano Mercadante
@en
Sebastiano Mercadante
@es
Sebastiano Mercadante
@nl
P214
P21
P214
P31
P496
0000-0001-9859-6487
P734
P7859
viaf-313518334